After screening the core therapeutic ingredients, a PPI network was constructed to determine core targets; our results showed that AKT1, CASP3, EGFR, ESR1, IGF1, MAPK1, and MAPK14 are important for AB–DA treatment of osteoporosis. This evidence concerns the gene AKT1 and osteoporosis.